Kenneth Ward Lyles, MD

Professor of Medicine
Senior Fellow in the Center for the Study of Aging and Human Development
Campus mail Duke Box 3881, Durham, NC 27710
Phone (919) 660-7520
Email address kenneth.lyles@duke.edu

My research activities focus on understanding ways that osteoporotic fractures affect people and trying to learn ways to reduce their impact on affected individuals and prevent further fractures. I have worked with patient with hip and vertebral fractures, gaining insight into the impairments such fractures cause. Also we have learned that a hip fracture is a major risk factor for subsequent fractures after the initial hip fracture. Our group completed a randomized, placebo-controlled trial that we designed with Novartis Pharmaceutical Corporation showing, that an annual infusion of a 5mg of the bisphosphonate zoledronic acid reduced subsequent fractures after a surgical procedure for a hip fracture by 35% when compared to a place infusion (New England Journal of Medicine, 11-1-07). In this study we also observed a 28% reduction in death in the zoledronic acid treated patients. Other research groups have shown that oral bisphosphonates also reduce mortality in patients with osteoporosis. Currently, we, with a number of collaborators, are conducting both animal and human studies to better understand this beneficial effect upon mortality.

In other work, our group tries to understand how other diseases such as strokes and spinal cord injury, and medications such as anticonvulsants place patients at risk for fractures. As we understand the epidemiology of these types of fractures, we plan to develop intervention trials to test whether we can reduce the occurrence of these fractures.

In addition to the above described work our group has help design and conduct a number of phase 1,2 and 3 clinical trials in Paget's disease of Bone and osteoporosis.

KEY WORDS:
Oteoporosis
Hip and vertebra fractures
Paget's disease of bone
Mobility impairments from metabolic bone diseases
Bisphosphonates

Education and Training

  • M.D., Virginia Commonwealth University, 1974

Publications

Adachi, JD, Lyles, KW, Colón-Emeric, CS, Boonen, S, Pieper, CF, Mautalen, C, Hyldstrup, L, Recknor, C, Nordsletten, L, Moore, KA, Bucci-Rechtweg, C, Su, G, Eriksen, EF, and Magaziner, JS. "Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial." Osteoporos Int 22, no. 9 (September 2011): 2539-2549.

PMID
21249332
Full Text

Reid, IR, Lyles, K, Su, G, Brown, JP, Walsh, JP, del Pino-Montes, J, Miller, PD, Fraser, WD, Cafoncelli, S, Bucci-Rechtweg, C, and Hosking, DJ. "A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years." Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research 26, no. 9 (September 2011): 2261-2270.

PMID
21638319
Full Text

Colón-Emeric, C, Nordsletten, L, Olson, S, Major, N, Boonen, S, Haentjens, P, Mesenbrink, P, Magaziner, J, Adachi, J, Lyles, KW, Hyldstrup, L, Bucci-Rechtweg, C, Recknor, C, and HORIZON Recurrent Fracture Trial, . "Association between timing of zoledronic acid infusion and hip fracture healing." Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the Usa 22, no. 8 (August 2011): 2329-2336.

PMID
21153021
Full Text

Colón-Emeric, CS, Lyles, KW, Su, G, Pieper, CF, Magaziner, JS, Adachi, JD, Bucci-Rechtweg, CM, Haentjens, P, Boonen, S, and HORIZON Recurrent Fracture Trial, . "Clinical risk factors for recurrent fracture after hip fracture: a prospective study." Calcif Tissue Int 88, no. 5 (May 2011): 425-431.

PMID
21331567
Full Text

Zammar, GR, Shah, J, Ferreira, APB, Cofiel, L, Lyles, KW, and Pietrobon, R. "Qualitative analysis of the interdisciplinary interaction between data analysis specialists and novice clinical researchers. (Published online)" PLoS One 5, no. 2 (February 24, 2010): e9400-.

PMID
20195374
Full Text

Boonen, S, Black, DM, Colón-Emeric, CS, Eastell, R, Magaziner, JS, Eriksen, EF, Mesenbrink, P, Haentjens, P, and Lyles, KW. "Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older." Journal of the American Geriatrics Society 58, no. 2 (February 2010): 292-299.

PMID
20070415
Full Text

Lee, RH, Lyles, KW, and Colón-Emeric, C. "A review of the effect of anticonvulsant medications on bone mineral density and fracture risk." The American Journal of Geriatric Pharmacotherapy 8, no. 1 (February 2010): 34-46. (Review)

PMID
20226391
Full Text

Colón-Emeric, CS, Mesenbrink, P, Lyles, KW, Pieper, CF, Boonen, S, Delmas, P, Eriksen, EF, and Magaziner, J. "Potential mediators of the mortality reduction with zoledronic acid after hip fracture." Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research 25, no. 1 (January 2010): 91-97.

PMID
19580467
Full Text

Grbic, JT, Black, DM, Lyles, KW, Reid, DM, Orwoll, E, McClung, M, Bucci-Rechtweg, C, and Su, G. "The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: Data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program." Journal of the American Dental Association 141, no. 11 (2010): 1365-1370.

PMID
21037195
Scholars@Duke

Colón-Emeric, CS, and Lyles, KW. "Should there be a fracas over FRAX and other fracture prediction tools?: Comment on "A comparison of prediction models for fractures in older women"." Arch Intern Med 169, no. 22 (December 14, 2009): 2094-2095.

PMID
20008692
Full Text

Pages